摘要
目的观察应用门冬氨酸鸟氨酸联合乳果糖治疗肝硬化所并发肝性脑病的疗效。方法 68例肝性脑病患者被随机分为乙酰谷酰胺治疗组17例、门冬氨酸鸟氨酸治疗组28例、门冬氨酸鸟氨酸联合乳果糖治疗组23例。结果 25%(7/28)门冬氨酸鸟氨酸治疗组患者,21.7%(5/23)联合治疗组患者死亡,而47.1%(8/17)乙酰谷酰胺治疗组患者死亡。死亡率有差异性P<0.05。结论在基础治疗的前提下,应用门冬氨酸鸟氨酸治疗肝性脑病在降低血浆氨、减少死亡率、改善肝肾功能等方面有一定效果,联合乳果糖后可明显减少死亡率,减少并发症的发生。
Aim To explore the effect of L-ornithine-L-aspartate combined with lactulose in the treatment of patients with hepatic encephalopathy after hepatic cirrhosis.Methods 68 patients with hepatic encephalopathy were selected and 17 patients received treatment of aceglutamide,28 patients received treatment of L-ornithine-L-aspartate and other 23 L-ornithine-L-aspartate combined with lactulose.Result The mortality rate,similar to that in L-ornithine-L-aspartate therapy（25%）,in L-ornithine-L-aspartate combined with lactulose treatment was 21.7%,much lower than that in aceglutamide treatment group（47.1%,P〈0.05）.Conclusion L-ornithine-L-aspartate combined with lactulose in the treatment of patients with hepatic encephalopathy can effectively decrease the mortality rate.
出处
《安徽医药》
CAS
2010年第9期1076-1078,共3页
Anhui Medical and Pharmaceutical Journal
关键词
肝性脑病
门冬氨酸鸟氨酸
乳果糖
HE（hepatic encephalopathy）
L-ornithine-L-aspartate
lactulose
